20-F/A - ETAO International Co., Ltd. (0001939696) (Filer)
6-K - ETAO International Co., Ltd. (0001939696) (Filer)
NT 20-F - ETAO International Co., Ltd. (0001939696) (Filer)
6-K - ETAO International Co., Ltd. (0001939696) (Filer)
20-F/A - ETAO International Co., Ltd. (0001939696) (Filer)
6-K - ETAO International Co., Ltd. (0001939696) (Filer)
6-K - ETAO International Co., Ltd. (0001939696) (Filer)
NEW YORK, Dec. 21, 2023 /PRNewswire/ -- The board of directors (the "Board") of ETAO International Co. Ltd. (the "Company") approved the appointment of Ryoshin Nakade, as ETAO Japan president of the Company, effective on November 22, 2023. Wensheng (Wilson) Liu, Chairman and CEO of ETAO stated, "We are thrilled about ETAO's new appointment of Ryoshin Nakade as ETAO Japan president. With the support of Mr. Ryoshin Nakade, ETAO would scale up its 'Buy Build and Expand' and 'Online Merging Offline 'strategy in Asian market quickly. We hope that in turn would speed up the development and market penetration of ETAO's integrated healthcare services for global customers." ETAO Announces Appointmen
This press release has been corrected to include further details regarding the reverse stock split of ETAO International Co., Ltd. We hereby issue a formal amendment to supersede our previously released press release dated March 19, 2024. This amended communication is intended to replace the original statement in its entirety and provides updated, accurate information. We advise all stakeholders to refer to this latest version for the most current details regarding the matter previously addressed. NEW YORK, March 21, 2024 /PRNewswire/ -- ETAO International Co., Ltd. (the "Company," "we" or "ETAO") (NASDAQ:ETAO), today announced that a 1 for 20 reverse split of its ordinary shares, an increas
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- ETAO International Co. Ltd. announced today that it received a staff determination – Delinquency letter (the "Letter"), on January 5, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company has not yet filed its interim financial statements for the period ended June 30, 2023 (the "Filing"), it no longer complies with our Listing Rules (the "Rules") for continued listing. Accordingly, this matter serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. Under Nasdaq rules, a Company that receives a delist determination for delinquency, can request an appea
NEW YORK, Dec. 21, 2023 /PRNewswire/ -- The board of directors (the "Board") of ETAO International Co. Ltd. (the "Company") approved the appointment of Ryoshin Nakade, as ETAO Japan president of the Company, effective on November 22, 2023. Wensheng (Wilson) Liu, Chairman and CEO of ETAO stated, "We are thrilled about ETAO's new appointment of Ryoshin Nakade as ETAO Japan president. With the support of Mr. Ryoshin Nakade, ETAO would scale up its 'Buy Build and Expand' and 'Online Merging Offline 'strategy in Asian market quickly. We hope that in turn would speed up the development and market penetration of ETAO's integrated healthcare services for global customers." ETAO Announces Appointmen
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- ETAO International Co. Ltd. announced today that it received a staff determination letter (the "Letter"), on December 13, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the determination from the Nasdaq staff (the "Staff") to delist the Company's securities from The Nasdaq Stock Market, because, as of December 11, 2023, the Company has not regained compliance with the bid price requirement as set forth Listing Rule 5550(a)(2) and is not eligible for a second 180 day period. ETAO International Co. Ltd. Received Nasdaq Delisting DeterminationPursuant to the Letter, unless the Company r
NEW YORK, Oct. 12, 2023 /PRNewswire/ -- ETAO International Co. Ltd. announces its plan of reorganization to dispose seven of its twelve consolidated affiliates subsidiaries to trim its operations and improve profitability. On October 11, 2023, pursuant to the terms of the Exclusive Business Cooperation Agreement, ETao Healthcare, the Company's indirectly subsidiary in China, notified Zhichao Medical Technology (Hunan) Co., Ltd., Beijing DNurse Technology Co., Ltd., Kang Ning (Heng Yang) Healthcare Management Co., Ltd., Tianlun (Guiyang) Buyun Buyu Hospital Co., Ltd., Qianhu Medical Management (Jiangxi) Co., Ltd., Chain Workshop (Beijing) Co., Ltd., Baihui (Beijing) Biotech Co., Ltd. and each
NEW YORK, June 22, 2023 /PRNewswire/ -- On June 14, 2023, Etao International Co., Ltd. (the "Company") received a bid price deficiency letter from The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that listed securities to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. However, the Rules also provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, NASDAQ will provide the Comp
NEW YORK, May 26, 2023 /PRNewswire/ -- On May 18, 2023, Etao International Co., Ltd. (the "Company") received a deficiency letter from The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it no longer complies with Nasdaq's Listing Rule 5250(c)(1) due to its failure to file Form 20-F for the period ended December 31, 2022 (the "Filing"). Nasdaq informed the Company that it has sixty (60) calendar days to submit a plan (the "Plan") to Nasdaq detailing how the Company plans to regain compliance with Nasdaq's continued listing requirements. If Nasdaq accepts the Company's proposed Plan, Nasdaq can grant an exception of up to one hundred-eighty (180) calendar days from the filing's